BiotechTube

Tulisokibart + Placebo

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Radiographic Axial Spondyloarthritis

Conditions

Radiographic Axial Spondyloarthritis

Trial Timeline

Sep 26, 2025 → Feb 5, 2030

NCT ID
NCT07133633

About Tulisokibart + Placebo

Tulisokibart + Placebo is a phase 2 stage product being developed by Merck for Radiographic Axial Spondyloarthritis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07133633. Target conditions include Radiographic Axial Spondyloarthritis.

What happened to similar drugs?

1 of 5 similar drugs in Radiographic Axial Spondyloarthritis were approved

Approved (1) Terminated (0) Active (4)
✅Secukinumab + Placebo + SecukinumabNovartisApproved
🔄SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 3
🔄Secukinumab + PlaceboNovartisPhase 3
🔄Secukinumab + PlaceboNovartisPhase 3
🔄BimekizumabUCBPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT07486960Phase 2Recruiting
NCT07133633Phase 2Recruiting
NCT06956235Phase 2Active
NCT06829225Phase 1Completed
NCT05270668Phase 2Active

Competing Products

6 competing products in Radiographic Axial Spondyloarthritis

See all competitors
ProductCompanyStageHype Score
SUNPG1622 I dose + Placebo doseSun PharmaceuticalPhase 2
27
SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 3
36
Secukinumab + PlaceboNovartisPhase 3
40
Secukinumab + Placebo + SecukinumabNovartisApproved
47
Secukinumab + PlaceboNovartisPhase 3
40
BimekizumabUCBPhase 3
40